Published online Mar 28, 2023. doi: 10.4329/wjr.v15.i3.56
Peer-review started: December 18, 2022
First decision: January 31, 2023
Revised: February 12, 2023
Accepted: March 22, 2023
Article in press: March 22, 2023
Published online: March 28, 2023
Processing time: 99 Days and 5.1 Hours
Primary liver cancer is the fourth most common malignancy worldwide, with hepatocellular carcinoma (HCC) comprising up to 90% of cases. Imaging is a staple for surveillance and diagnostic criteria for HCC in current guidelines. Because early diagnosis can impact treatment approaches, utilizing new imaging methods and protocols to aid in differentiation and tumor grading provides a unique opportunity to drastically impact patient prognosis. Within this review manuscript, we provide an overview of imaging modalities used to screen and evaluate HCC. We also briefly discuss emerging uses of new imaging techniques that offer the potential for improving current paradigms for HCC characterization, management, and treatment monitoring.
Core Tip: Successful tumor assessment can be a critical component to patient management and prognosis. The expansion of imaging techniques beyond conventional modalities (e.g. ultrasound, computed tomography, magnetic resonance imaging) provides an opportunity to improve the identification of small or well-differentiated hepatocellular carcinoma tumors, along with the capability to monitor treatment responses to surgery or locoregional therapy.